HOME >>

FDA Joint Advisory Committee Votes in Favor of Perrigo’s Opill® Daily Oral Contraceptive for OTC Use

By

[ad_1]

FDA Joint Advisory Committee Votes in Favor of Perrigo’s Opill® Daily Oral Contraceptive for OTC Use

DUBLIN, May 10, 2023 /PRNewswire/ — Perrigo Company plc (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced today that the U.S….

[ad_2]

Source link

댓글 달기

이메일 주소는 공개되지 않습니다. 필수 필드는 *로 표시됩니다

Recent Posts: